Motif ID | Motif Logo | Scanned Score Distribution | Frequency of Motif | Replicability Score | Evolutionary Conservation Score | Gene Targets | Gene Ontology of CpGMM targets |
---|---|---|---|---|---|---|---|
CG_h9_promoter_n_RM_12_9_6 | ![]() |
![]() |
2 | 0.5 | 2.87E-04 | SUV420H1, ACSS1 | histone H4-K20 trimethylation [BP], acetate biosynthetic process [BP], acetyl-CoA biosynthetic process from acetate [BP], propionate biosynthetic process [BP] |
CG_h9_promoter_n_RM_12_99_5 | ![]() |
![]() |
3 | 0.5 | 2.73E-04 | ASTL | glutamic-type peptidase activity [MF], cortical granule [CC] |
CG_h9_promoter_n_RM_12_203_7 | ![]() |
![]() |
4 | 0.75 | 2.95E-04 | BMP4, KPNA1, IRS2, GLI3 | cell differentiation involved in kidney development [BP], cranial suture morphogenesis [BP], mammary gland formation [BP], thymocyte apoptotic process [BP], dorsal/ventral neural tube patterning [BP], mammary gland development [BP], positive regulation of protein import into nucleus [BP] |
CG_h9_promoter_n_RM_12_52_5 | ![]() |
![]() |
4 | 0.5 | 2.41E-04 | NOTCH1, AQP3, JAG2 | regulation of keratinocyte differentiation [BP], somatic stem cell division [BP], auditory receptor cell fate commitment [BP], Notch receptor processing [BP] |
CG_h9_promoter_n_RM_14_1_2 | ![]() |
![]() |
7 | 1.0 | 1.03E-04 | TMED1, BCAP31 | endoplasmic reticulum-Golgi intermediate compartment membrane [CC], endoplasmic reticulum-Golgi intermediate compartment [CC] |
CG_h9_promoter_n_RM_12_186_4 | ![]() |
![]() |
3 | 0.5 | 1.97E-04 | HYI, KIF17, HYAL2, TESC, SEC22C | hydroxypyruvate isomerase activity [MF], protein kinase inhibitor activity [MF], receptor signaling protein tyrosine kinase inhibitor activity [MF], protein transport [BP] |
CG_h9_promoter_n_RM_12_50_2 | ![]() |
![]() |
2 | 0.5 | 2.23E-04 | OTOF, PTGIR, DLGAP3, TBX5, HOMER1, STAR | cellular response to luteinizing hormone stimulus [BP], response to nicotine [BP], cell-cell signaling [BP], synaptic vesicle exocytosis [BP], cell migration involved in coronary vasculogenesis [BP] |
CG_h9_promoter_n_RM_12_136_3 | ![]() |
![]() |
2 | 0.5 | 1.74E-04 | ASTL, WASL, CDK5, CNR1 | regulation of nitric-oxide synthase activity [BP], cortical granule [CC], membrane budding [BP], response to cocaine [BP], synaptic transmission, glutamatergic [BP] |
CG_h9_promoter_n_RM_12_172_8 | ![]() |
![]() |
3 | 0.75 | 1.88E-04 | FLII, CEP76, TLN1, HAUS4 | centrosome [CC] |
CG_h9_promoter_n_RM_14_20_2 | ![]() |
![]() |
3 | 0.5 | 7.14E-04 | MEX3D | mRNA localization resulting in posttranscriptional regulation of gene expression [BP] |
CG_h9_promoter_n_RM_12_105_2 | ![]() |
![]() |
3 | 0.5 | 4.21E-04 | EGR2 | rhombomere 3 formation [BP], rhombomere 5 formation [BP] |
CG_h9_promoter_n_RM_12_97_2 | ![]() |
![]() |
3 | 0.5 | 2.59E-04 | GGH | gamma-glutamyl-peptidase activity [MF] |
CG_h9_promoter_n_RM_12_85_3 | ![]() |
![]() |
2 | 0.5 | 3.77E-04 | SLC6A4 | negative regulation of cerebellar granule cell precursor proliferation [BP], serotonin:sodium symporter activity [MF], cocaine binding [MF] |
CG_h9_promoter_n_RM_12_207_7 | ![]() |
![]() |
4 | 0.75 | 3.60E-04 | GRIN2C, USP4, GRIN2B, GLI3, CDK5, LHX3 | N-methyl-D-aspartate selective glutamate receptor complex [CC], cerebral cortex radial glia guided migration [BP], regulation of excitatory postsynaptic membrane potential [BP], ventral spinal cord interneuron specification [BP], postsynaptic density [CC], extracellular-glutamate-gated ion channel activity [MF], outer membrane-bounded periplasmic space [CC], negative regulation of protein ubiquitination [BP], motor neuron axon guidance [BP], spinal cord motor neuron cell fate specification [BP], N-methyl-D-aspartate selective glutamate receptor activity [MF] |
CG_h9_promoter_n_RM_12_107_11 | ![]() |
![]() |
3 | 0.5 | 3.91E-04 | ACOX1, SLC27A5 | very long-chain fatty acid metabolic process [BP] |
CG_h9_promoter_n_RM_12_19_5 | ![]() |
![]() |
6 | 0.75 | 3.82E-04 | ZRANB3, STK10 | DNA rewinding [BP], polo kinase kinase activity [MF] |
CG_h9_promoter_n_RM_12_22_2 | ![]() |
![]() |
2 | 0.5 | 4.64E-04 | M1AP, ZRANB3, CDK5, BAZ1A | DNA rewinding [BP], male meiosis chromosome separation [BP], ACF complex [CC], acetylcholine receptor activator activity [MF] |
CG_h9_promoter_n_RM_12_201_5 | ![]() |
![]() |
4 | 0.75 | 3.00E-04 | CD34 | glomerular endothelium fenestra [CC], negative regulation of cellular response to hypoxia [BP], negative regulation of cellular response to heat [BP], sulfate binding [MF], extracellular vesicular exosome assembly [BP], positive regulation of glial cell line-derived neurotrophic factor secretion [BP] |
CG_h9_promoter_n_RM_12_196_2 | ![]() |
![]() |
2 | 0.5 | 4.01E-04 | IRX3, DLL1 | negative regulation of neuron differentiation [BP], loop of Henle development [BP], negative regulation of auditory receptor cell differentiation [BP] |
CG_h9_promoter_n_RM_12_20_8 | ![]() |
![]() |
4 | 0.75 | 2.24E-04 | PCSK7, ST6GAL2 | integral to Golgi membrane [CC] |
CG_h9_promoter_n_RM_12_42_4 | ![]() |
![]() |
4 | 0.5 | 2.93E-04 | NPY1R, AGTPBP1, NPC1 | locomotory behavior [BP], adult walking behavior [BP] |
CG_h9_promoter_n_RM_12_188_4 | ![]() |
![]() |
5 | 0.75 | 4.29E-04 | HOXA1, ECHDC1 | optokinetic behavior [BP], abducens nerve formation [BP], methylmalonyl-CoA decarboxylase activity [MF] |
CG_h9_promoter_n_RM_12_39_6 | ![]() |
![]() |
3 | 0.5 | 4.76E-04 | FLOT2, HSPA5, ANAPC2 | positive regulation of protein ubiquitination [BP], ubiquitin protein ligase binding [MF], endoplasmic reticulum chaperone complex [CC], regulation of protein folding in endoplasmic reticulum [BP], flotillin complex [CC], cerebellum structural organization [BP] |
CG_h9_promoter_n_RM_12_87_4 | ![]() |
![]() |
4 | 0.75 | 3.27E-04 | GHSR, HSPD1 | growth hormone secretagogue receptor activity [MF], positive regulation of T cell mediated immune response to tumor cell [BP], B cell cytokine production [BP], regulation of hindgut contraction [BP], positive regulation of appetite [BP] |
CG_h9_promoter_n_RM_12_7_5 | ![]() |
![]() |
5 | 0.75 | 3.08E-04 | NAGPA, ENTPD4, SERPINE2, GBX2 | mating plug formation [BP], cerebellum development [BP], seminal vesicle epithelium development [BP], UDP catabolic process [BP], N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase activity [MF] |
CG_h9_promoter_n_RM_12_170_4 | ![]() |
![]() |
3 | 0.75 | 9.02E-05 | DDX17 | regulation of skeletal muscle cell differentiation [BP] |
CG_h9_promoter_n_RM_14_9_3 | ![]() |
![]() |
5 | 0.75 | 1.36E-04 | TRMT61B | mitochondrial tRNA methylation [BP] |
CG_h9_promoter_n_RM_12_108_5 | ![]() |
![]() |
2 | 0.5 | 2.80E-04 | RBBP7, RLIM, SFRP4, DCTPP1, NODAL | transforming growth factor beta receptor signaling pathway involved in primitive streak formation [BP], negative regulation of sodium-dependent phosphate transport [BP], epiblast cell-extraembryonic ectoderm cell signaling involved in anterior/posterior axis specification [BP], axial mesodermal cell fate specification [BP], pyrimidine deoxyribonucleotide binding [MF], random inactivation of X chromosome [BP], dCTP diphosphatase activity [MF], cellular heat acclimation [BP], inhibition of neuroepithelial cell differentiation [BP] |
CG_h9_promoter_n_RM_12_35_4 | ![]() |
![]() |
4 | 0.75 | 2.36E-04 | NKX3-1, DDX17 | positive regulation of androgen secretion [BP], MADS box domain binding [MF], positive regulation of response to DNA damage stimulus [BP], estrogen receptor binding [MF] |
CG_h9_promoter_n_RM_12_132_4 | ![]() |
![]() |
4 | 1.0 | 3.39E-04 | GATA2, ADAM10, TFRC, JAG2, SLC18A1, SLC8A2, NUP210, SLC25A41 | constitutive protein ectodomain proteolysis [BP], transmembrane transport [BP], Notch receptor processing [BP], Notch signaling pathway [BP], negative regulation of fat cell proliferation [BP] |
CG_h9_promoter_n_RM_12_89_7 | ![]() |
![]() |
3 | 0.75 | 1.14E-04 | CYP11A1, DARS | cholesterol monooxygenase (side-chain-cleaving) activity [MF], response to fungicide [BP], aspartyl-tRNA aminoacylation [BP], fractalkine metabolic process [BP], aspartate-tRNA ligase activity [MF], granulosa cell differentiation [BP], response to genistein [BP] |
CG_h9_promoter_n_RM_12_182_4 | ![]() |
![]() |
3 | 0.5 | 4.08E-04 | NFATC2, EN1, CAMK2B, DLL1, TNIP1, GDNF, SFRP2 | peptidyl-serine phosphorylation [BP], positive regulation of transcription from RNA polymerase II promoter [BP] |
CG_h9_promoter_n_RM_12_25_6 | ![]() |
![]() |
3 | 0.5 | 4.65E-04 | CD34, ABCA2 | lysosome [CC], negative regulation of cellular response to hypoxia [BP], glomerular endothelium fenestra [CC], negative regulation of cellular response to heat [BP], sulfate binding [MF], extracellular vesicular exosome assembly [BP], positive regulation of glial cell line-derived neurotrophic factor secretion [BP] |
CG_h9_promoter_n_RM_12_160_4 | ![]() |
![]() |
3 | 0.75 | 1.58E-04 | WNT5A, ATG3 | Atg8 ligase activity [MF], receptor tyrosine kinase-like orphan receptor binding [MF] |
CG_h9_promoter_n_RM_12_91_6 | ![]() |
![]() |
1 | 0.25 | 5.82E-05 | UBXN6, GANAB, TFAP2A | cellular response to iron ion [BP], oculomotor nerve formation [BP], microtubule organizing center [CC], anterior neuropore closure [BP], optic vesicle morphogenesis [BP], optic cup structural organization [BP], glucosidase II complex [CC], glucan 1,3-alpha-glucosidase activity [MF] |
CG_h9_promoter_n_RM_12_130_3 | ![]() |
![]() |
3 | 0.5 | 3.95E-04 | HEY1, AKT1 | atrioventricular valve formation [BP], labyrinthine layer blood vessel development [BP], glycogen cell differentiation involved in embryonic placenta development [BP] |
CG_h9_promoter_n_RM_12_209_5 | ![]() |
![]() |
3 | 0.75 | 2.86E-04 | EZH2 | cerebellar cortex development [BP] |
CG_h9_promoter_n_RM_12_12_6 | ![]() |
![]() |
2 | 0.5 | 2.93E-04 | GIP, COPS2, SIX5, FGFR2, SGMS1, RNF216, BCAR1, BMP4 | prostate gland morphogenesis [BP], cell proliferation [BP], bud elongation involved in lung branching [BP], lung alveolus development [BP], branching involved in prostate gland morphogenesis [BP], regulation of smooth muscle cell differentiation [BP], epithelial tube branching involved in lung morphogenesis [BP], lateral sprouting from an epithelium [BP], regulation of branching involved in prostate gland morphogenesis [BP], cranial suture morphogenesis [BP], digestive system development [BP], apoptotic process [BP], negative regulation of mitosis [BP], epithelial cell proliferation involved in lung morphogenesis [BP], mammary gland formation [BP], lens development in camera-type eye [BP] |
CG_h9_promoter_n_RM_14_12_5 | ![]() |
![]() |
6 | 1.0 | 2.11E-04 | SDC4, KDR, AMBP | calcium oxalate binding [MF], positive regulation of focal adhesion assembly [BP] |
CG_h9_promoter_n_RM_12_103_6 | ![]() |
![]() |
4 | 0.5 | 4.45E-04 | HOXA2 | rhombomere 3 morphogenesis [BP], rhombomere 2 development [BP] |
CG_h9_promoter_n_RM_12_118_5 | ![]() |
![]() |
3 | 0.5 | 3.50E-04 | TNFRSF10D, TNFRSF10B | TRAIL binding [MF] |
CG_h9_promoter_n_RM_12_31_6 | ![]() |
![]() |
3 | 0.75 | 1.66E-04 | DNMT3A | S-adenosylhomocysteine metabolic process [BP], DNA (cytosine-5-)-methyltransferase activity, acting on CpG substrates [MF] |
CG_h9_promoter_n_RM_12_16_8 | ![]() |
![]() |
3 | 0.75 | 2.62E-04 | GANAB, TRMT61B, POU4F1, SLC5A6, SCTR, DBN1, TRPT1, CYP2J2 | mitochondrial tRNA methylation [BP], secretin receptor activity [MF], pantothenate transmembrane transport [BP], proprioception involved in equilibrioception [BP], tRNA 2'-phosphotransferase activity [MF], arachidonic acid 11,12-epoxygenase activity [MF], biotin transport [BP], arachidonic acid 14,15-epoxygenase activity [MF], cell communication by chemical coupling [BP], linoleic acid epoxygenase activity [MF], glucosidase II complex [CC], glucan 1,3-alpha-glucosidase activity [MF] |
CG_h9_promoter_n_RM_12_66_6 | ![]() |
![]() |
4 | 0.75 | 4.88E-04 | HS6ST1, PLCD3, BSCL2, DDHD1 | lipid catabolic process [BP], labyrinthine layer blood vessel development [BP] |
CG_h9_promoter_n_RM_12_176_5 | ![]() |
![]() |
3 | 0.75 | 2.61E-04 | TLN1, CDK5 | cortical actin cytoskeleton organization [BP] |
CG_h9_promoter_n_RM_12_54_2 | ![]() |
![]() |
2 | 0.5 | 3.22E-04 | SRXN1 | sulfiredoxin activity [MF] |
CG_h9_promoter_n_RM_12_101_6 | ![]() |
![]() |
5 | 0.75 | 3.11E-04 | CEBPA, NKX2-5, ADI1 | transcription regulatory region DNA binding [MF], polyamine metabolic process [BP] |
CG_h9_promoter_n_RM_12_180_9 | ![]() |
![]() |
3 | 0.75 | 2.33E-04 | ESR2, NKX3-1, WNT11, ATF2, PYCARD | cysteine-type endopeptidase activator activity involved in apoptotic process [MF], regulation of intrinsic apoptotic signaling pathway [BP], estrogen receptor activity [MF], positive regulation of transforming growth factor beta2 production [BP] |
CG_h9_promoter_n_RM_14_7_2 | ![]() |
![]() |
5 | 0.75 | 1.68E-04 | BCAT2 | isoleucine catabolic process [BP] |
CG_h9_promoter_n_RM_12_134_6 | ![]() |
![]() |
2 | 0.5 | 3.10E-04 | UROC1 | urocanate hydratase activity [MF] |
CG_h9_promoter_n_RM_12_29_3 | ![]() |
![]() |
4 | 0.75 | 1.71E-04 | CLDN19, CLDN6, CLIP3 | calcium-independent cell-cell adhesion [BP], ganglioside binding [MF] |
CG_h9_promoter_n_RM_12_95_5 | ![]() |
![]() |
2 | 0.5 | 2.71E-04 | GANAB | glucosidase II complex [CC], glucan 1,3-alpha-glucosidase activity [MF] |
CG_h9_promoter_n_RM_12_81_4 | ![]() |
![]() |
5 | 0.75 | 2.53E-04 | NAGPA, WT1 | N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase activity [MF], negative regulation of metanephric glomerular mesangial cell proliferation [BP] |
CG_h9_promoter_n_RM_12_106_5 | ![]() |
![]() |
3 | 0.5 | 2.20E-04 | FRAT2, PARK2, MAF, AKT1 | multicellular organismal development [BP], negative regulation of release of cytochrome c from mitochondria [BP], regulation of chondrocyte differentiation [BP], cell differentiation [BP] |
CG_h9_promoter_n_RM_12_83_10 | ![]() |
![]() |
3 | 0.5 | 3.48E-04 | TXNL4A, MCL1, CAMK2B, SCTR | inhibitory G-protein coupled receptor phosphorylation [BP], secretin receptor activity [MF], nucleoplasm [CC] |
CG_h9_promoter_n_RM_12_121_3 | ![]() |
![]() |
5 | 0.75 | 2.05E-04 | SMAD2 | activating transcription factor binding [MF] |
CG_h9_promoter_n_RM_12_202_3 | ![]() |
![]() |
3 | 0.75 | 2.16E-04 | HEYL, TNIP1, FZD5, CSNK1D, SFRP2 | AF-1 domain binding [MF], negative regulation of dermatome development [BP], metalloenzyme activator activity [MF], modulation by symbiont of host I-kappaB kinase/NF-kappaB cascade [BP], Wnt-activated receptor activity [MF], positive regulation of canonical Wnt receptor signaling pathway [BP], Wnt-protein binding [MF], outflow tract morphogenesis [BP], canonical Wnt receptor signaling pathway [BP] |
CG_h9_promoter_n_RM_12_146_8 | ![]() |
![]() |
6 | 0.75 | 3.41E-04 | RACGAP1, IRS2, PPP2R2B, TIMM13, TUBGCP3, BCL6 | negative regulation of B cell apoptotic process [BP], gamma-tubulin binding [MF], protein targeting to mitochondrion [BP] |
CG_h9_promoter_n_RM_12_92_3 | ![]() |
![]() |
2 | 0.5 | 2.11E-04 | PLOD3, POLDIP3 | procollagen glucosyltransferase activity [MF], intracellular membrane-bounded organelle [CC] |
CG_h9_promoter_n_RM_12_185_5 | ![]() |
![]() |
3 | 0.5 | 4.03E-04 | ADAM12, YBX2, PITX2 | translation regulator activity [MF], myoblast fusion [BP] |
CG_h9_promoter_n_RM_12_139_3 | ![]() |
![]() |
2 | 0.5 | 2.20E-04 | PGGT1B, ARFGEF1, SLC4A11 | phosphoenolpyruvate-dependent sugar phosphotransferase system [BP], CAAX-protein geranylgeranyltransferase complex [CC], borate transmembrane transporter activity [MF], positive regulation of protein glycosylation in Golgi [BP], borate transport [BP], borate transmembrane transport [BP] |
CG_h9_promoter_n_RM_12_98_5 | ![]() |
![]() |
2 | 0.5 | 4.61E-04 | LBX1 | regulation of transcription from RNA polymerase II promoter involved in spinal cord association neuron specification [BP] |
CG_h9_promoter_n_RM_12_58_6 | ![]() |
![]() |
4 | 0.75 | 3.65E-04 | PRICKLE1, BAZ2A | heterochromatin assembly involved in chromatin silencing [BP], negative regulation of cardiac muscle cell myoblast differentiation [BP] |
CG_h9_promoter_n_RM_12_189_3 | ![]() |
![]() |
3 | 0.75 | 2.25E-04 | ESR2, AFAP1L2, STAT1, JUN, PKD1, HSPG2, RBBP7, PLA2G16, HOXA7, C1orf86, PAX3, NDNL2, BCL6, RALGAPA2, IRX2, GNL1 | angiogenesis [BP], anatomical structure morphogenesis [BP], positive regulation of transcription, DNA-dependent [BP], negative regulation of transcription from RNA polymerase II promoter [BP], monocyte differentiation [BP], renal tubule development [BP], organ morphogenesis [BP], regulation of transcription, DNA-dependent [BP], negative regulation of cell-matrix adhesion [BP], positive regulation of smooth muscle cell proliferation [BP], sequence-specific DNA binding [MF], negative regulation of transcription, DNA-dependent [BP], GTP catabolic process [BP], protein binding [MF], chromosomal part [CC], core promoter sequence-specific DNA binding [MF], negative regulation of cell growth [BP], sequence-specific DNA binding transcription factor activity [MF], transcription from RNA polymerase II promoter [BP], cell-matrix adhesion [BP], nucleus [CC] |
CG_h9_promoter_n_RM_12_49_5 | ![]() |
![]() |
3 | 0.5 | 3.08E-04 | HOXA5, NOTCH1, FKBP1A, JAG2 | Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation [BP], respiratory system process [BP], auditory receptor cell fate commitment [BP], Notch receptor processing [BP], ventricular cardiac muscle tissue morphogenesis [BP], regulation of extracellular matrix assembly [BP], heart trabecula morphogenesis [BP], cell-cell signaling involved in mammary gland development [BP], venous endothelial cell differentiation [BP] |
CG_h9_promoter_n_RM_12_206_5 | ![]() |
![]() |
3 | 0.5 | 2.37E-04 | GAS1, FGF3, HOXA1, ALX3 | embryonic skeletal system morphogenesis [BP], optokinetic behavior [BP], abducens nerve formation [BP], semicircular canal morphogenesis [BP], embryonic cranial skeleton morphogenesis [BP], pattern specification process [BP], outer ear morphogenesis [BP] |
CG_h9_promoter_n_RM_12_10_4 | ![]() |
![]() |
4 | 0.75 | 3.63E-04 | HYAL2, GRIN2A, TFAP2A | regulation of excitatory postsynaptic membrane potential [BP], optic vesicle morphogenesis [BP], receptor signaling protein tyrosine kinase inhibitor activity [MF], optic cup structural organization [BP] |
CG_h9_promoter_n_RM_12_70_3 | ![]() |
![]() |
2 | 0.5 | 3.12E-04 | PIGU | GPI-anchor transamidase complex [CC] |
CG_h9_promoter_n_RM_12_190_2 | ![]() |
![]() |
4 | 0.75 | 3.12E-04 | ZNF350, EZH2, RBBP7, TRMT61B, RENBP | transcriptional repressor complex [CC], cellular heat acclimation [BP], mitochondrial tRNA methylation [BP], N-acylglucosamine 2-epimerase activity [MF], ESC/E(Z) complex [CC] |
CG_h9_promoter_n_RM_12_44_4 | ![]() |
![]() |
2 | 0.5 | 1.14E-04 | CLK1, FGFR2, INSRR, SIK1, FOXA1 | prostate gland morphogenesis [BP], protein tyrosine kinase activity [MF], fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow [BP], fibroblast growth factor receptor signaling pathway involved in hemopoiesis [BP], prostate gland epithelium morphogenesis [BP], protein autophosphorylation [BP], fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow [BP], cellular response to alkalinity [BP], epithelial tube branching involved in lung morphogenesis [BP], coronal suture morphogenesis [BP] |
CG_h9_promoter_n_RM_12_5_4 | ![]() |
![]() |
2 | 0.5 | 4.57E-04 | ALDH4A1, AIPL1, DACT2, COL5A3 | skin development [BP], farnesylated protein binding [MF], 1-pyrroline-5-carboxylate dehydrogenase activity [MF] |
CG_h9_promoter_n_RM_12_140_3 | ![]() |
![]() |
2 | 0.5 | 2.93E-04 | NKX3-1, CDKN1C | negative regulation of epithelial cell proliferation [BP], positive regulation of androgen secretion [BP], MADS box domain binding [MF] |
CG_h9_promoter_n_RM_12_53_2 | ![]() |
![]() |
2 | 0.5 | 3.90E-04 | CRLF1 | negative regulation of motor neuron apoptotic process [BP] |
CG_h9_promoter_n_RM_12_200_6 | ![]() |
![]() |
3 | 0.75 | 1.55E-04 | WNT7A, NUP62, LATS2 | synapse organization [BP], hormone-mediated signaling pathway [BP] |
CG_h9_promoter_n_RM_12_3_3 | ![]() |
![]() |
3 | 0.5 | 2.54E-04 | ZGLP1, ALX4, ADNP, CXCR4, BARHL2 | sequence-specific DNA binding [MF], myosin light chain binding [MF] |
CG_h9_promoter_n_RM_12_72_5 | ![]() |
![]() |
3 | 0.5 | 2.84E-04 | DBR1, HNRNPR | RNA splicing [BP], RNA lariat debranching enzyme activity [MF] |
CG_h9_promoter_n_RM_14_8_2 | ![]() |
![]() |
4 | 0.75 | 5.73E-04 | DBR1, NKX3-1, RUNX1 | positive regulation of androgen secretion [BP], positive regulation of progesterone secretion [BP], MADS box domain binding [MF], RNA lariat debranching enzyme activity [MF] |
CG_h9_promoter_n_RM_12_192_7 | ![]() |
![]() |
2 | 0.5 | 2.98E-04 | TOLLIP, CELSR1, HID1 | protein localization involved in establishment of planar polarity [BP], response to brefeldin A [BP], interleukin-18 receptor complex [CC], extrinsic to Golgi membrane [CC] |
CG_h9_promoter_n_RM_12_129_2 | ![]() |
![]() |
3 | 0.75 | 4.31E-04 | IPMK, OPRK1 | inositol tetrakisphosphate 3-kinase activity [MF], inositol-1,4,5-trisphosphate 6-kinase activity [MF], dynorphin receptor activity [MF] |
CG_h9_promoter_n_RM_12_133_4 | ![]() |
![]() |
2 | 0.5 | 3.51E-04 | SLC4A11 | borate transmembrane transporter activity [MF], borate transport [BP], phosphoenolpyruvate-dependent sugar phosphotransferase system [BP], borate transmembrane transport [BP] |
CG_h9_promoter_n_RM_12_33_5 | ![]() |
![]() |
2 | 0.5 | 2.81E-04 | HOXA2 | rhombomere 3 morphogenesis [BP], rhombomere 2 development [BP] |
CG_h9_promoter_n_RM_12_120_3 | ![]() |
![]() |
2 | 0.5 | 4.09E-04 | NAGPA, ACSS1 | acetate biosynthetic process [BP], N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase activity [MF], propionate biosynthetic process [BP] |
CG_h9_promoter_n_RM_12_154_4 | ![]() |
![]() |
3 | 0.75 | 2.45E-04 | FGF8, HOXB3 | thyroid gland development [BP] |
CG_h9_promoter_n_RM_12_41_7 | ![]() |
![]() |
3 | 0.5 | 3.93E-04 | SRCIN1, MYO10, CYGB | filopodium [CC], neuronal cell body [CC] |
CG_h9_promoter_n_RM_12_73_5 | ![]() |
![]() |
2 | 0.5 | 3.18E-04 | YPEL1, HYAL2, FGF3 | semicircular canal morphogenesis [BP], regulation of myelination [BP], negative regulation of protein kinase B signaling cascade [BP] |
CG_h9_promoter_n_RM_12_195_5 | ![]() |
![]() |
6 | 0.75 | 3.33E-04 | MAFB, JAK3, CDK6, PLXNA2 | cerebellar granule cell precursor tangential migration [BP], rhombomere 6 development [BP], negative regulation of FasL biosynthetic process [BP], regulation of erythrocyte differentiation [BP], cell dedifferentiation [BP] |
CG_h9_promoter_n_RM_12_131_3 | ![]() |
![]() |
3 | 0.75 | 3.25E-04 | CSNK1D | regulation of circadian rhythm [BP] |
CG_h9_promoter_n_RM_12_197_6 | ![]() |
![]() |
3 | 0.5 | 3.12E-04 | ACD, TMEM123 | oncosis [BP], positive regulation of single-stranded telomeric DNA binding [BP] |
CG_h9_promoter_n_RM_12_198_2 | ![]() |
![]() |
3 | 0.5 | 1.83E-04 | DAP | cellular response to amino acid starvation [BP] |
CG_h9_promoter_n_RM_12_32_4 | ![]() |
![]() |
2 | 0.5 | 3.38E-04 | SV2A, SLC30A3, HOOK2 | endocytosis [BP], synaptic vesicle membrane [CC] |
CG_h9_promoter_n_RM_12_143_4 | ![]() |
![]() |
4 | 0.75 | 1.62E-04 | TEFM | DNA polymerase processivity factor activity [MF] |
CG_h9_promoter_n_RM_12_84_2 | ![]() |
![]() |
4 | 0.75 | 1.17E-04 | PSMD10, GPLD1, ABCB6, SLC30A1, COQ3, SUMO2 | GPI anchor release [BP], negative regulation of zinc ion transmembrane import [BP], heme-transporting ATPase activity [MF], 2-polyprenyl-6-methoxy-1,4-benzoquinone methyltransferase activity [MF], cadmium ion transmembrane transport [BP], glycosylphosphatidylinositol phospholipase D activity [MF], positive regulation of proteasomal ubiquitin-dependent protein catabolic process [BP], 3-demethylubiquinone-9 3-O-methyltransferase activity [MF], detoxification of cadmium ion [BP], hexaprenyldihydroxybenzoate methyltransferase activity [MF], cellular response to triglyceride [BP] |
CG_h9_promoter_n_RM_12_34_2 | ![]() |
![]() |
3 | 0.75 | 1.83E-04 | PTGR1, BCAT1, NANP | branched-chain amino acid biosynthetic process [BP], N-acylneuraminate-9-phosphatase activity [MF], 2-alkenal reductase [NAD(P)] activity [MF], N-acetylneuraminate biosynthetic process [BP], N-acetylglucosamine biosynthetic process [BP] |
CG_h9_promoter_n_RM_12_116_8 | ![]() |
![]() |
4 | 1.0 | 5.31E-04 | HOXB5, HOXB3 | embryonic skeletal system morphogenesis [BP], rhombomere development [BP] |
CG_h9_promoter_n_RM_12_156_5 | ![]() |
![]() |
3 | 0.75 | 3.68E-04 | FGFR2 | negative regulation of mitosis [BP] |
CG_h9_promoter_n_RM_12_45_5 | ![]() |
![]() |
2 | 0.5 | 4.80E-04 | FKBP1A | peptidyl-proline modification [BP] |
CG_h9_promoter_n_RM_14_6_2 | ![]() |
![]() |
3 | 0.75 | 5.90E-04 | HYAL1 | hyaluranon cable [CC] |
CG_h9_promoter_n_RM_12_78_2 | ![]() |
![]() |
3 | 0.75 | 1.88E-04 | KDSR, LDB1, LHX5, EPHA4 | DH domain binding [MF], transcription-dependent tethering of RNA polymerase II gene DNA at nuclear periphery [BP], 3-dehydrosphinganine reductase activity [MF], cerebellar Purkinje cell differentiation [BP], 3-keto-sphinganine metabolic process [BP], sphingolipid biosynthetic process [BP], histone H3-K4 acetylation [BP], positive regulation of Rho guanyl-nucleotide exchange factor activity [BP] |
CG_h9_promoter_n_RM_12_64_4 | ![]() |
![]() |
3 | 0.5 | 2.68E-04 | MYO1C, FH | fumarate hydratase activity [MF], myosin I complex [CC], positive regulation of vascular endothelial growth factor signaling pathway [BP] |
CG_h9_promoter_n_RM_12_96_8 | ![]() |
![]() |
4 | 0.75 | 3.08E-04 | AMPH, IPMK, CCT4, NADKD1, DVL1, BRAF, PLCD3, MAPK1, ILF2, TOR2A, CDK5, CNR1 | synaptic transmission [BP], synaptic vesicle endocytosis [BP], response to epidermal growth factor stimulus [BP], peptidyl-serine phosphorylation [BP], sensory perception of pain [BP], receptor clustering [BP], labyrinthine layer blood vessel development [BP], ATP binding [MF] |
CG_h9_promoter_n_RM_12_30_3 | ![]() |
![]() |
2 | 0.5 | 4.32E-04 | VGF | response to cold [BP] |
CG_h9_promoter_n_RM_12_183_4 | ![]() |
![]() |
2 | 0.5 | 2.15E-04 | TBX5, SURF6 | nucleoplasm part [CC], cell migration involved in coronary vasculogenesis [BP] |
CG_h9_promoter_n_RM_12_199_2 | ![]() |
![]() |
2 | 0.5 | 3.25E-04 | RORA | cGMP metabolic process [BP] |
CG_h9_promoter_n_RM_12_137_4 | ![]() |
![]() |
3 | 0.5 | 4.62E-04 | PEMT | phosphatidylethanolamine N-methyltransferase activity [MF], phosphatidyl-N-dimethylethanolamine N-methyltransferase activity [MF], phosphatidyl-N-methylethanolamine N-methyltransferase activity [MF] |
CG_h9_promoter_n_RM_12_94_3 | ![]() |
![]() |
3 | 0.75 | 3.41E-04 | GLRX2, CALCR | arsenate reductase (glutaredoxin) activity [MF], calcitonin binding [MF] |
CG_h9_promoter_n_RM_14_15_2 | ![]() |
![]() |
4 | 0.5 | 3.29E-04 | MTHFSD, PRKCQ | 5-formyltetrahydrofolate cyclo-ligase activity [MF], positive regulation of T-helper 2 cell activation [BP] |
CG_h9_promoter_n_RM_12_48_4 | ![]() |
![]() |
3 | 0.5 | 3.83E-04 | TBX20, APIP, SHANK1, STAT1, SHH | patterning of blood vessels [BP], somatostatin receptor binding [MF], methylthioribulose 1-phosphate dehydratase activity [MF], metanephric mesenchymal cell proliferation involved in metanephros development [BP], positive regulation of mesenchymal cell proliferation [BP], heart looping [BP], pattern specification process [BP] |
CG_h9_promoter_n_RM_12_181_2 | ![]() |
![]() |
3 | 0.75 | 2.02E-04 | MYO10, RBBP7 | cellular heat acclimation [BP], plus-end directed microfilament motor activity [MF] |
CG_h9_promoter_n_RM_12_102_3 | ![]() |
![]() |
3 | 0.5 | 3.38E-04 | VAV2, DTYMK, CDK5, HAND2, GAS1, MYH10 | embryonic digit morphogenesis [BP], adult heart development [BP], nucleoside monophosphate phosphorylation [BP], cerebellum morphogenesis [BP], cell migration [BP], axon guidance [BP], nucleoside phosphate kinase activity [MF], neuromuscular junction [CC], positive regulation of semaphorin-plexin signaling pathway involved in outflow tract morphogenesis [BP], acetylcholine receptor activator activity [MF], positive regulation of transcription from RNA polymerase II promoter involved in norepinephrine biosynthetic process [BP] |
CG_h9_promoter_n_RM_12_55_2 | ![]() |
![]() |
3 | 0.5 | 3.86E-04 | HOXA5, TNS3 | cell-cell signaling involved in mammary gland development [BP], lung alveolus development [BP] |
CG_h9_promoter_n_RM_12_152_3 | ![]() |
![]() |
2 | 0.5 | 1.77E-04 | NUMBL, SHH | CD4-positive or CD8-positive, alpha-beta T cell lineage commitment [BP], neuroblast proliferation [BP], intein-mediated protein splicing [BP], right lung development [BP], mesenchymal smoothened signaling pathway involved in prostate gland development [BP], regulation of mesenchymal cell proliferation involved in prostate gland development [BP], neuroblast division in subventricular zone [BP], positive regulation of skeletal muscle cell proliferation [BP], negative regulation of kidney smooth muscle cell differentiation [BP], positive regulation of epithelial cell proliferation involved in prostate gland development [BP], epithelial-mesenchymal signaling involved in prostate gland development [BP], negative regulation of ureter smooth muscle cell differentiation [BP], primary prostatic bud elongation [BP], positive regulation of kidney smooth muscle cell differentiation [BP], positive regulation of ureter smooth muscle cell differentiation [BP], positive regulation of sclerotome development [BP], multicellular structure septum development [BP] |
CG_h9_promoter_n_RM_12_59_3 | ![]() |
![]() |
3 | 0.5 | 1.96E-04 | SRD5A2, WT1 | sterol 5-alpha reductase activity [MF], negative regulation of metanephric glomerular mesangial cell proliferation [BP] |
CG_h9_promoter_n_RM_12_168_4 | ![]() |
![]() |
3 | 0.75 | 3.68E-04 | RUNX1, GPLD1, MMS22L, UBE2N, RECQL4 | DNA recombination [BP], GPI anchor release [BP], cellular response to triglyceride [BP], double-strand break repair via homologous recombination [BP], positive regulation of progesterone secretion [BP], glycosylphosphatidylinositol phospholipase D activity [MF] |
CG_h9_promoter_n_RM_12_204_6 | ![]() |
![]() |
3 | 0.5 | 2.98E-04 | PLXNB1, HOMER1 | semaphorin-plexin signaling pathway [BP], regulation of calcium ion import [BP] |
CG_h9_promoter_n_RM_12_147_6 | ![]() |
![]() |
3 | 0.75 | 2.58E-04 | NACA | negative regulation of transcription from RNA polymerase II promoter involved in heart development [BP], nascent polypeptide-associated complex [CC] |
CG_h9_promoter_n_RM_12_43_5 | ![]() |
![]() |
3 | 0.5 | 2.33E-04 | LSM4 | U6 snRNP [CC] |
CG_h9_promoter_n_RM_12_194_4 | ![]() |
![]() |
6 | 0.75 | 1.23E-04 | UROC1 | urocanate hydratase activity [MF] |
CG_h9_promoter_n_RM_12_145_2 | ![]() |
![]() |
4 | 0.75 | 4.20E-04 | AMOTL2, AXIN2, HSPA5, NKX2-5, STX8 | proepicardium development [BP], Wnt receptor signaling pathway [BP], ubiquitin protein ligase binding [MF], positive regulation of voltage-gated calcium channel activity [BP], Purkinje myocyte differentiation [BP], regulation of protein folding in endoplasmic reticulum [BP], atrioventricular node cell fate commitment [BP], regulation of chondrocyte development [BP] |
CG_h9_promoter_n_RM_12_82_4 | ![]() |
![]() |
5 | 0.75 | 4.59E-04 | TNK2, ERBB4, MAD1L1 | epidermal growth factor receptor binding [MF], mitotic telophase [BP], cardiac muscle tissue regeneration [BP] |
CG_h9_promoter_n_RM_12_76_5 | ![]() |
![]() |
2 | 0.5 | 2.31E-04 | ANKLE2, TGFB1 | positive regulation of protein dephosphorylation [BP], lens fiber cell differentiation [BP] |
CG_h9_promoter_n_RM_12_149_4 | ![]() |
![]() |
4 | 0.75 | 1.51E-04 | SIN3A, TXNRD2 | response to methylglyoxal [BP], response to oxygen radical [BP], negative regulation of histone H3-K27 acetylation [BP] |
CG_h9_promoter_n_RM_12_110_4 | ![]() |
![]() |
5 | 0.75 | 2.26E-04 | FASN, FBXW5, DCAF5, ANKLE2 | 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activity [MF], 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activity [MF], enoyl-[acyl-carrier-protein] reductase (NADPH, B-specific) activity [MF], [acyl-carrier-protein] S-acetyltransferase activity [MF], 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity [MF], Cul4-RING ubiquitin ligase complex [CC], mitotic nuclear envelope reassembly [BP] |
CG_h9_promoter_n_RM_12_2_3 | ![]() |
![]() |
4 | 0.5 | 1.92E-04 | JUP, GEM, BVES | epithelial cell-cell adhesion [BP], internal side of plasma membrane [CC], lateral plasma membrane [CC] |
CG_h9_promoter_n_RM_12_208_3 | ![]() |
![]() |
2 | 0.5 | 2.50E-04 | EZH2 | chromatin organization [BP], histone methyltransferase activity [MF], pronucleus [CC], histone-lysine N-methyltransferase activity [MF] |
CG_h9_promoter_n_RM_12_36_2 | ![]() |
![]() |
3 | 0.5 | 4.75E-04 | MEX3D, LSS, SNAI2 | desmosome disassembly [BP], mRNA localization resulting in posttranscriptional regulation of gene expression [BP], negative regulation of stem cell proliferation [BP], lanosterol synthase activity [MF], negative regulation of cell-cell adhesion by negative regulation of transcription from RNA polymerase II promoter [BP], negative regulation of vitamin D receptor signaling pathway [BP] |
CG_h9_promoter_n_RM_14_21_6 | ![]() |
![]() |
5 | 0.5 | 3.33E-04 | PFN2 | regulation of synaptic vesicle exocytosis [BP] |
CG_h9_promoter_n_RM_12_68_6 | ![]() |
![]() |
2 | 0.5 | 3.97E-04 | VPS53, OCA2, ALG5, ALG2 | dolichol-linked oligosaccharide biosynthetic process [BP], endosome membrane [CC] |
CG_h9_promoter_n_RM_12_112_2 | ![]() |
![]() |
4 | 0.5 | 2.86E-04 | AMBP | calcium oxalate binding [MF] |
CG_h9_promoter_n_RM_12_88_5 | ![]() |
![]() |
3 | 0.75 | 2.08E-04 | SMARCA1 | helicase activity [MF], ATP-dependent chromatin remodeling [BP] |
CG_h9_promoter_n_RM_12_74_3 | ![]() |
![]() |
2 | 0.5 | 2.01E-04 | FOXA2, TPT1, FGF8, CITED1 | response to interleukin-11 [BP], cell migration involved in mesendoderm migration [BP], response to interleukin-6 [BP], regulation of transcription from RNA polymerase II promoter involved in detection of glucose [BP], embryonic axis specification [BP], endoderm development [BP], branching involved in ureteric bud morphogenesis [BP], dopaminergic neuron differentiation [BP], signal transduction involved in regulation of gene expression [BP], negative regulation of detection of glucose [BP], negative regulation of transcription from RNA polymerase II promoter by glucose [BP], negative regulation of ectoderm development [BP], lung morphogenesis [BP] |
CG_h9_promoter_n_RM_12_38_4 | ![]() |
![]() |
3 | 0.5 | 3.80E-04 | WNT10B, CHRM4, PLOD3 | positive regulation of anagen [BP], procollagen glucosyltransferase activity [MF], procollagen galactosyltransferase activity [MF], procollagen-lysine 5-dioxygenase activity [MF], myoblast cell differentiation involved in skeletal muscle regeneration [BP], basement membrane assembly [BP], neural tube development [BP], adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway [BP] |
CG_h9_promoter_n_RM_12_193_8 | ![]() |
![]() |
6 | 0.75 | 3.19E-04 | HOXA1 | motor neuron axon guidance [BP] |
CG_h9_promoter_n_RM_12_205_11 | ![]() |
![]() |
4 | 0.75 | 2.01E-04 | PPP3CA, ANKLE2, SLC5A6, XBP1, LSM4 | biotin transport [BP], epithelial cell maturation involved in salivary gland development [BP], pantothenate transmembrane transport [BP], mitotic nuclear envelope reassembly [BP], serotonin secretion, neurotransmission [BP], U6 snRNP [CC], transition between fast and slow fiber [BP] |
CG_h9_promoter_n_RM_12_60_3 | ![]() |
![]() |
2 | 0.5 | 3.37E-04 | AXIN2 | regulation of chondrocyte development [BP] |
CG_h9_promoter_n_RM_12_155_2 | ![]() |
![]() |
2 | 0.5 | 2.28E-04 | ANXA7 | nuclear envelope [CC] |
CG_h9_promoter_n_RM_12_141_4 | ![]() |
![]() |
3 | 0.75 | 2.83E-04 | TRMT61B, NOTCH1, CARD9, SNTA1 | response to muramyl dipeptide [BP], Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation [BP], regulation of extracellular matrix assembly [BP], mitochondrial tRNA methylation [BP], venous endothelial cell differentiation [BP], regulation of vasoconstriction by circulating norepinephrine [BP] |
CG_h9_promoter_n_RM_12_23_3 | ![]() |
![]() |
3 | 0.75 | 1.71E-04 | CD34, SLC22A6 | glomerular endothelium fenestra [CC], renal tubular secretion [BP], negative regulation of cellular response to hypoxia [BP], negative regulation of cellular response to heat [BP], sulfate binding [MF], extracellular vesicular exosome assembly [BP], positive regulation of glial cell line-derived neurotrophic factor secretion [BP] |
CG_h9_promoter_n_RM_12_46_4 | ![]() |
![]() |
3 | 0.5 | 2.72E-04 | CSNK1D, PRICKLE1 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process [BP] |
CG_h9_promoter_n_RM_14_17_1 | ![]() |
![]() |
2 | 0.5 | 3.36E-04 | HOXA5, OCA2, ALG2 | GDP-Man:Man1GlcNAc2-PP-Dol alpha-1,3-mannosyltransferase activity [MF], arsenite transmembrane transporter activity [MF], protein glycosylation in endoplasmic reticulum [BP], L-tyrosine transmembrane transporter activity [MF], cell-cell signaling involved in mammary gland development [BP], arsenite transport [BP], tyrosine transport [BP] |
CG_h9_promoter_n_RM_12_79_3 | ![]() |
![]() |
2 | 0.5 | 3.12E-04 | STRA13, TONSL | replication fork processing [BP] |
CG_h9_promoter_n_RM_12_122_7 | ![]() |
![]() |
2 | 0.5 | 3.46E-04 | DLL1, NOTCH1, NDN, RACGAP1 | left/right axis specification [BP], compartment pattern specification [BP], neuronal stem cell maintenance [BP], Notch receptor processing [BP], gamma-tubulin binding [MF] |
CG_h9_promoter_n_RM_12_67_7 | ![]() |
![]() |
3 | 0.75 | 2.65E-04 | HOXA5 | positive regulation of receptor biosynthetic process [BP] |
CG_h9_promoter_n_RM_12_153_4 | ![]() |
![]() |
2 | 0.5 | 2.95E-04 | FBXO5, NEK2 | spindle assembly involved in female meiosis I [BP], regulation of mitosis [BP], spindle assembly [BP], inhibition of mitotic anaphase-promoting complex activity [BP] |
CG_h9_promoter_n_RM_14_19_1 | ![]() |
![]() |
2 | 0.5 | 6.69E-04 | TSC1 | rRNA export from nucleus [BP], TSC1-TSC2 complex [CC] |
CG_h9_promoter_n_RM_12_178_7 | ![]() |
![]() |
6 | 0.75 | 3.40E-04 | SMAD7, BCAR1, PCID2, GLI3 | anterior semicircular canal development [BP], lambdoid suture morphogenesis [BP], lateral ganglionic eminence cell proliferation [BP], regulation of apoptotic process [BP], lateral semicircular canal development [BP], sagittal suture morphogenesis [BP], beta-catenin binding [MF], negative regulation of apoptotic process [BP], artery development [BP] |
CG_h9_promoter_n_RM_12_124_3 | ![]() |
![]() |
3 | 0.5 | 4.99E-04 | CDKN2A, SMAD7, FGFR2, KIAA0368, NACC2 | somatic stem cell division [BP], ventricular septum morphogenesis [BP], ventricular cardiac muscle tissue morphogenesis [BP], endoplasmic reticulum [CC], posttranscriptional regulation of gene expression [BP], negative regulation of mitosis [BP], cellular protein complex localization [BP] |
CG_h9_promoter_n_RM_12_77_4 | ![]() |
![]() |
3 | 0.5 | 3.38E-04 | HDAC3, WNT10B, RANGAP1, NOTCH1, E2F8, ABCA2, ATF6B, KCTD1, SLC4A11 | regulation of extracellular matrix assembly [BP], positive regulation of anagen [BP], phosphoenolpyruvate-dependent sugar phosphotransferase system [BP], Ran GTPase activator activity [MF], transcription corepressor activity [MF], negative regulation of transcription from RNA polymerase II promoter [BP], myoblast cell differentiation involved in skeletal muscle regeneration [BP], Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation [BP], chromatin DNA binding [MF], anagen [BP], sprouting angiogenesis [BP], transcription, DNA-dependent [BP], negative regulation of transcription, DNA-dependent [BP], positive regulation of Ran GTPase activity [BP], borate transmembrane transporter activity [MF], cell cycle comprising mitosis without cytokinesis [BP], venous endothelial cell differentiation [BP], positive regulation of epithelial cell differentiation [BP], borate transport [BP], borate transmembrane transport [BP], regulation of transcription from RNA polymerase II promoter [BP] |
CG_h9_promoter_n_RM_12_177_6 | ![]() |
![]() |
3 | 0.5 | 3.51E-04 | HOXA5 | cell-cell signaling involved in mammary gland development [BP] |
CG_h9_promoter_n_RM_12_86_10 | ![]() |
![]() |
4 | 0.75 | 2.20E-04 | MGEA5, MMS19, NEUROD2 | negative regulation of cardiac muscle adaptation [BP], cerebellar cortex development [BP], phosphorelay signal transduction system [BP] |
CG_h9_promoter_n_RM_12_71_4 | ![]() |
![]() |
3 | 0.75 | 2.17E-04 | UGDH, GCH1, IL6ST, MOCS1, NACC2, EIF2B1, HIBCH, EEF2, RAB27A | interleukin-11 binding [MF], GTP binding [MF], UDP-glucose 6-dehydrogenase activity [MF], negative regulation of G1/S transition of mitotic cell cycle by negative regulation of transcription from RNA polymerase II promoter [BP], GDP binding [MF], secretory granule membrane [CC], ciliary neurotrophic factor receptor complex [CC], negative regulation of interleukin-6-mediated signaling pathway [BP], cytotoxic T cell degranulation [BP], 3-hydroxyisobutyryl-CoA hydrolase activity [MF], interleukin-11 receptor activity [MF], GTP cyclohydrolase I activity [MF], 7,8-dihydroneopterin 3'-triphosphate biosynthetic process [BP], interleukin-27-mediated signaling pathway [BP] |
CG_h9_promoter_n_RM_12_175_2 | ![]() |
![]() |
2 | 0.5 | 3.00E-04 | NUDT18, MED1, VDR, TAF12 | retinoic acid receptor binding [MF], GDP catabolic process [BP], DNA-dependent transcription, initiation [BP], 8-oxo-GDP phosphatase activity [MF], 8-oxo-dGDP phosphatase activity [MF], vitamin D3 receptor activity [MF], transcription initiation from RNA polymerase II promoter [BP], negative regulation of keratinocyte proliferation [BP], dADP catabolic process [BP], dGDP catabolic process [BP], vitamin D receptor signaling pathway [BP], 8-hydroxy-dADP phosphatase activity [MF], positive regulation of keratinocyte differentiation [BP] |
CG_h9_promoter_n_RM_12_167_4 | ![]() |
![]() |
5 | 0.75 | 3.09E-04 | RUNX1, ALX4, CEBPA | positive regulation of progesterone secretion [BP], response to vitamin B2 [BP], HMG box domain binding [MF] |
CG_h9_promoter_n_RM_12_18_5 | ![]() |
![]() |
4 | 0.75 | 4.90E-04 | DEGS2, DLG4, LPHN1 | P2Y1 nucleotide receptor binding [MF], sphingolipid delta-4 desaturase activity [MF], sphingosine hydroxylase activity [MF], axon [CC] |
CG_h9_promoter_n_RM_12_26_4 | ![]() |
![]() |
4 | 0.5 | 3.65E-04 | PGF, RUNX1, CD34, DTYMK, TWIST1 | glomerular endothelium fenestra [CC], negative regulation of cellular response to hypoxia [BP], nucleoside monophosphate phosphorylation [BP], extracellular vesicular exosome assembly [BP], sulfate binding [MF], positive regulation of progesterone secretion [BP], positive regulation of angiogenesis [BP], negative regulation of tumor necrosis factor production [BP], positive regulation of endocardial cushion to mesenchymal transition involved in heart valve formation [BP], nucleoside phosphate kinase activity [MF], hematopoietic stem cell proliferation [BP], negative regulation of cellular response to heat [BP], cell proliferation involved in heart valve development [BP], positive regulation of glial cell line-derived neurotrophic factor secretion [BP] |
CG_h9_promoter_n_RM_12_90_3 | ![]() |
![]() |
2 | 0.5 | 1.42E-04 | RAB38 | phagosome acidification [BP] |
CG_h9_promoter_n_RM_12_161_5 | ![]() |
![]() |
3 | 0.75 | 2.42E-04 | PAX6, PDGFA | regulation of branching involved in salivary gland morphogenesis by epithelial-mesenchymal signaling [BP], salivary gland morphogenesis [BP], commitment of neuronal cell to specific neuron type in forebrain [BP], regulation of transcription from RNA polymerase II promoter involved in somatic motor neuron fate commitment [BP], pancreatic A cell development [BP], forebrain-midbrain boundary formation [BP] |
CG_h9_promoter_n_RM_12_75_8 | ![]() |
![]() |
6 | 0.75 | 3.28E-04 | PTK2, RGS7, GNAQ, AKT1 | positive regulation of blood vessel endothelial cell migration [BP], endothelial cell migration [BP], osteoblast differentiation [BP], fat cell differentiation [BP], regulation of endothelial cell migration [BP], heterotrimeric G-protein complex [CC], regulation of action potential [BP] |
CG_h9_promoter_n_RM_12_115_9 | ![]() |
![]() |
4 | 0.75 | 4.54E-04 | HOXB3, GNA13, SLC4A7, GBX2, PLXND1 | patterning of blood vessels [BP], retinal cell programmed cell death [BP], rhombomere development [BP] |
CG_h9_promoter_n_RM_12_104_2 | ![]() |
![]() |
3 | 0.5 | 3.18E-04 | CEBPA, SH3YL1, C2CD5, P2RX1 | external side of cell outer membrane [CC], response to vitamin B2 [BP], ruffle membrane [CC] |
CG_h9_promoter_n_RM_14_22_7 | ![]() |
![]() |
5 | 0.5 | 3.61E-04 | TAF12, EDF1 | transcription factor TFIID complex [CC] |
CG_h9_promoter_n_RM_12_13_4 | ![]() |
![]() |
4 | 0.75 | 3.96E-04 | CCNE2 | cyclin-dependent protein kinase regulator activity [MF] |
CG_h9_promoter_n_RM_12_211_2 | ![]() |
![]() |
3 | 0.75 | 2.49E-04 | RNF168, ABO, MGAT1 | fucosylgalactoside 3-alpha-galactosyltransferase activity [MF], histone H2A-K15 ubiquitination [BP], glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase activity [MF], alpha-1,3-mannosylglycoprotein 2-beta-N-acetylglucosaminyltransferase activity [MF], histone H2A-K13 ubiquitination [BP], UDP-N-acetylglucosamine catabolic process [BP] |
CG_h9_promoter_n_RM_12_109_7 | ![]() |
![]() |
4 | 0.75 | 5.97E-04 | GLRX2, OCA2, MTFMT | DNA protection [BP], L-tyrosine transmembrane transporter activity [MF], arsenate reductase (glutaredoxin) activity [MF], arsenite transport [BP], methionyl-tRNA formyltransferase activity [MF], tyrosine transport [BP] |
CG_h9_promoter_n_RM_12_164_3 | ![]() |
![]() |
3 | 0.5 | 2.18E-04 | NAGPA, INPP5K, IP6K1, BCOR, PITX2 | positive regulation of renal water transport [BP], phosphatidylinositol phosphorylation [BP], negative regulation of histone H3-K36 methylation [BP], prolactin secreting cell differentiation [BP], N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase activity [MF], subthalamic nucleus development [BP], superior vena cava morphogenesis [BP] |
CG_h9_promoter_n_RM_12_11_4 | ![]() |
![]() |
2 | 0.5 | 2.28E-05 | SHOX2 | positive regulation of skeletal muscle fiber development [BP], regulation of branching morphogenesis of a nerve [BP] |
CG_h9_promoter_n_RM_12_24_6 | ![]() |
![]() |
2 | 0.5 | 3.07E-04 | SCML2 | PcG protein complex [CC] |
CG_h9_promoter_n_RM_12_28_5 | ![]() |
![]() |
2 | 0.5 | 2.58E-04 | KIAA0368, VCP | ER-associated protein catabolic process [BP] |
CG_h9_promoter_n_RM_12_17_3 | ![]() |
![]() |
3 | 0.5 | 2.04E-04 | SRXN1, UGGT2, GLRX2, FASN | 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activity [MF], oxidoreductase activity, acting on a sulfur group of donors [MF], sulfiredoxin activity [MF], enoyl-[acyl-carrier-protein] reductase (NADPH, B-specific) activity [MF], [acyl-carrier-protein] S-acetyltransferase activity [MF], UDP-glucosylation [BP], 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activity [MF], 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity [MF], arsenate reductase (glutaredoxin) activity [MF] |
CG_h9_promoter_n_RM_12_179_4 | ![]() |
![]() |
2 | 0.5 | 2.29E-04 | FGFR2, HDDC3, ALX4, CD59 | negative regulation of activation of membrane attack complex [BP], fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow [BP], guanosine-3',5'-bis(diphosphate) 3'-diphosphatase activity [MF], fibroblast growth factor receptor signaling pathway involved in hemopoiesis [BP], regulation of apoptotic process [BP], fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow [BP], coronal suture morphogenesis [BP] |
CG_h9_promoter_n_RM_12_63_6 | ![]() |
![]() |
2 | 0.5 | 3.00E-04 | GIPC1 | myosin binding [MF] |
CG_h9_promoter_n_RM_12_37_4 | ![]() |
![]() |
2 | 0.5 | 2.64E-04 | STK10, NKX3-1, COQ2, TFAP2A | 4-hydroxybenzoate decaprenyltransferase activity [MF], core promoter binding [MF], MADS box domain binding [MF], salivary gland development [BP], polo kinase kinase activity [MF], optic cup structural organization [BP], positive regulation of androgen secretion [BP], optic vesicle morphogenesis [BP], 4-hydroxybenzoate nonaprenyltransferase activity [MF], negative regulation of mitotic cell cycle [BP] |
CG_h9_promoter_n_RM_12_15_6 | ![]() |
![]() |
4 | 1.0 | 2.66E-04 | TOB1, CEBPD, COPS2, THRB, DEAF1, NOTCH1, SOX21 | negative regulation of BMP signaling pathway [BP], chromatin DNA binding [MF], negative regulation of osteoblast differentiation [BP], transcription from RNA polymerase II promoter [BP], regulation of transcription from RNA polymerase II promoter [BP] |
CG_h9_promoter_n_RM_12_171_6 | ![]() |
![]() |
3 | 0.5 | 5.47E-04 | ZFHX3, POLR2E | transcription from RNA polymerase II promoter [BP] |
CG_h9_promoter_n_RM_14_11_3 | ![]() |
![]() |
3 | 0.75 | 9.74E-05 | ADAM8 | positive regulation of fibronectin-dependent thymocyte migration [BP], alpha9-beta1 integrin-ADAM8 complex [CC], positive regulation of eosinophil migration [BP], positive regulation of neutrophil extravasation [BP], dense core granule membrane [CC] |
CG_h9_promoter_n_RM_14_16_1 | ![]() |
![]() |
4 | 0.5 | 3.49E-04 | MCL1 | protein channel activity [MF] |